Richard Tsien, PhD, director of the Neuroscience Institute at NYU Langone Medical Center, will deliver the next web-based Discovery Lecture.

An FDA-approved medication enhances the function of T regulatory cells (Treg), a class of immune cells that restrains the immune response, Vanderbilt investigators have discovered.

Distinct cancer-associated fibroblasts in the prostate tumor microenvironment may influence tumor progression and could point to new therapeutic targets.

In HIV-positive individuals with diabetes, immune cells in fat are more proinflammatory and cytotoxic and may represent a therapeutic target for diabetes.

Dan Roden, MD, Senior Vice President for Personalized Medicine at Vanderbilt University Medical Center, received the Oscar B. Hunter Career Award in Therapeutics last week at the virtual annual meeting of the American Society for Clinical Pharmacology and Therapeutics.

A novel hormone deficiency may exist in humans, Vanderbilt investigators have discovered. In an analysis of two decades worth of electronic health records, the researchers found that some patients have unexpectedly low levels of natriuretic peptide hormone in clinical situations that should cause high levels of the hormone.